"An advanced Cancer Center where over 1,200 highly sub-specialized professionals work together in a multidisciplinary approach to bring customized solutions in a friendly and engaging environment to every patient."

During the past decade, Hackensack Meridian Health - John Theurer Cancer Center conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 3 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 2 clinical trials were completed. i.e. 18.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hackensack Meridian Health - John Theurer Cancer Center" #1 sponsor was "Merck Sharp & Dohme LLC" with 10 trials, followed by "Hackensack Meridian Health" with 2 trials sponsored, "AVEO Pharmaceuticals, Inc." with 1 trials sponsored, "Astex Pharmaceuticals, Inc." with 1 trials sponsored and "Dendreon" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hackensack Meridian Health - John Theurer Cancer Center" #1 collaborator was "Amgen" with 1 trials as a collaborator, "California Institute for Regenerative Medicine (CIRM)" with 1 trials as a collaborator, "Pharmacyclics LLC." with 1 trials as a collaborator and "University of California, San Diego" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Hackensack Meridian Health - John Theurer Cancer Center" are "Carcinoma, Non-Small-Cell Lung" (4 trials), "Prostatic Neoplasms" (2 trials), "Advanced Solid Tumors" (1 trials), "B-cell Chronic Lymphocytic Leukemia" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Hackensack Meridian Health - John Theurer Cancer Center" in a lesser frequency.

Most popular intervention types in "Hackensack Meridian Health - John Theurer Cancer Center" are "Drug" (13 trials), "Biological" (9 trials), "Device" (1 trials), "Diagnostic Test" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (8 trials), "MK-4830" (4 trials), "MK-0482" (3 trials), "Boserolimab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hackensack Meridian Health - John Theurer Cancer Center" are 15 trials for "All" genders, 3 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hackensack Meridian Health - John Theurer Cancer Center". undefined are not yet recruiting, 8 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Hackensack Meridian Health - John Theurer Cancer Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hackensack Meridian Health - John Theurer Cancer Center, 5 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".